FLAG-003
Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM)
PreclinicalActive
Key Facts
Indication
Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM)
Phase
Preclinical
Status
Active
Company
About FLAG Therapeutics
FLAG Therapeutics is a private, preclinical-stage biotech company developing small molecule oncology drugs for high-unmet-need cancers. Its strategy centers on three proprietary platforms that generate dual- or multi-action compounds, with an initial focus on pediatric DIPG and adult GBM. The company recently secured over $500,000 in equity and impact funding from a mix of venture and mission-driven investors. With lead program FLAG-003 on track for a Phase 1/2 trial in 2026, FLAG aims to address some of the most aggressive and lethal cancers.
View full company profile